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Secreted peptide growth factors are critical extracellular signals that interact to promote the proliferation, differentiation,
and survival of progenitor cells in developing tissues. IGF-I signaling through the IGF type I receptor provides a mitogenic
signal for numerous cell types, including stem and progenitor cells. We have utilized the O-2A oligodendrocyte progenitor
to study the mechanism of IGF-I mitogenic actions since these progenitors respond to IGF-I in vitro, and gene targeting
studies in mice have demonstrated that IGF-I is essential for normal oligodendrocyte development in vivo. The goal of this
study was to elucidate the mechanism by which IGF-I promotes the proliferation of oligodendrocyte progenitors in the
context of other mitogens critical for their proliferation. Results presented here show that IGF-I significantly amplified the
actions of FGF-2 and PDGF to promote DNA synthesis in O-2A progenitors. Investigation of cell cycle kinetics revealed that
IGF-I had no significant effect on the rate of cell cycle progression. Instead, IGF-I promoted increased recruitment of O-2A
progenitors into the S phase of the cell cycle. These studies support a role for IGF-I as a cell cycle progression factor for
progenitor cells. © 2001 Academic Press
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sINTRODUCTION
The control of proliferation, survival, and differentiation
of progenitor cells in developing tissues requires these cells
to integrate multiple extrinsic signals. The cellular re-
sponse to these signals depends on both the developmental
stage of the cell and the precise combination of signals that
the cell receives from the local environment. Secreted
peptide growth factors are among the extracellular signals
that influence progenitor cells to make decisions to con-
tinue proliferating or to differentiate. Insulin-like growth
factor-I (IGF-I) is a secreted peptide growth factor found in
the circulation and expressed in most developing and adult
tissues. Genetic deletion of IGF-I in mice results in general
growth defects as well as defects in development of specific
tissues, including the brain and reproductive tissues (Baker
et al., 1993, 1996; Beck et al., 1995; Cheng et al., 1998; Liu
et al., 1993). IGF-I is a mitogen and survival factor for
multiple cell types acting through its primary signaling
receptor, the IGF type I receptor (IGF-IR). IGF-I mitogenic
actions have been well documented for a wide variety of
developing and mature cell types, including stem and i
414rogenitor cells of the neural (Aberg et al., 2000) and
rythropoetic lineages (Frostad et al., 1988; Miyagawa et al.,
000), fibroblasts (Sell et al., 1994), pituitary cells (Prager et
l., 1992), and uterine (Adesanya et al., 1999) and mammary
pithelial cells (Richert and Wood, 1999).
One of the most highly studied cell lineages is the
ligodendrocyte lineage. The oligodendrocyte, the myelin-
roducing cell of the central nervous system, is derived
rom an early-stage progenitor known as the O-2A progeni-
or. The O-2A progenitor is a bipotential progenitor that can
ifferentiate into an oligodendrocyte or a type II astrocyte
epending on the extracellular signals (Raff et al., 1983).
esults of numerous studies have revealed much about how
rowth and trophic factors regulate the proliferation and
ifferentiation of sequentially restricted oligodendrocyte
rogenitors. Growth factors with demonstrated critical
oles in the generation of oligodendrocytes include platelet-
erived growth factor-A (PDGF-A), fibroblast growth
actor-2 (FGF-2), and IGF-I. Treatment of the O-2A progeni-
or in vitro with PDGF stimulates self-renewal through
everal cell cycles followed by subsequent differentiation
nto mature oligodendrocytes (Bo¨gler et al., 1990; Gard and
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415IGF-I and FGF-2 Synergism on O-2A ProgenitorsPfeiffer, 1993). FGF-2 also stimulates proliferation of O-2As
and of the later stage progenitor known as the pro-
oligodendroblast and blocks further differentiation of these
cells into oligodendrocytes (Bo¨gler et al., 1990; Gard and
Pfeiffer, 1993; McKinnon et al., 1993; Wolswijk and Noble,
1992). The combination of PDGF and FGF-2 results in
prolonged amplification of the early O-2A progenitors and
is widely used to amplify O-2A progenitors in vitro (Bo¨gler
et al., 1990; Gard and Pfeiffer, 1993; McKinnon et al., 1990,
1993).
While much of the evidence that PDGF and FGF-2 are
important for oligodendrocyte progenitor proliferation has
come from in vitro studies, several recent reports also
support a role for these factors in oligodendrocyte genera-
tion in vivo. Mice carrying a genetic deletion of the pdgf-A
gene have reduced numbers of oligodendrocyte progenitors
and mature oligodendrocytes and show tremors indicative
of a dysmyelinating phenotype (Fruttiger et al., 1999).
FGF-2 also is present during oligodendrocyte generation in
vivo (Giordano et al., 1992), and addition of exogenous
FGF-2 during late embryonic or early postnatal ages results
in increased numbers of oligodendrocytes (Goddard et al.,
1999; Vaccarino et al., 1999). Defects in oligodendroglial
numbers or in myelination have not been reported to date
in mice carrying a null mutation in the fgf-2 gene, although
these mice demonstrate neuronal defects throughout the
central nervous system due in part to an apparent migration
failure of neuronal precursors (Dono et al., 1998; Raballo et
al., 2000). Since the FGF family consists of more than 20
members (for review, see Mufson et al., 1999; Ornitz, 2000),
it is possible that compensatory changes in other FGF
ligand family members will complicate analysis of FGF-2
effects on oligodendrocyte development in FGF-2 null mu-
tant mice.
Numerous studies support the hypothesis that IGF-I also
is critical for oligodendrocyte generation. The amplification
of O-2A progenitors with PDGF and FGF-2 is commonly
carried out in the presence of micromolar levels of insulin,
levels sufficient to activate the IGF type I receptor (Rechler
and Nissley, 1985). IGF-I also is present during stages of
oligodendrocyte development in vivo (for review see
D’Ercole et al., 1996) and can promote proliferation as well
as survival and maturation of oligodendrocytes in vitro
(Barres et al., 1992, 1993; McMorris and Dubois-Dalcq,
1988; McMorris et al., 1986, 1990, 1993). Moreover, analy-
ses of transgenic and knockout mouse lines have provided
evidence for an essential role for this factor in oligodendro-
cyte generation. Overexpression of IGF-I in the brain leads
to hypermyelination and increased numbers of oligodendro-
cytes (Carson et al., 1993; Ye et al., 1995a), while deletion of
IGF-I is associated with hypomyelination and loss of oligo-
dendrocytes (Beck et al., 1995; Cheng et al., 1998). Analyses
of the effects of overexpression or genetic deletion of IGF-I
in mice have focused predominantly on the mature oligo-
dendrocyte; thus, an additional role for IGF-I in the prolif-
eration of oligodendrocyte progenitors has not been ana-
lyzed in vivo. Since IGF-I null mice demonstrate defects in
Copyright © 2001 by Academic Press. All rightnumbers of neurons, it is impossible to analyze direct
effects of IGF-I on the oligodendrocyte progenitors in these
mice. Moreover, mice that overexpress IGF-I that demon-
strate hypermyelination do not initiate transgene expres-
sion until postnatal ages (Carson et al., 1993; Ye et al.,
1995a, b), after the time when the majority of oligodendro-
cyte progenitors are generated and proliferate.
It is likely that the presence of multiple factors are
required in vivo to coordinately promote proliferation of
oligodendrocyte progenitors and generation of oligodendro-
cytes during development. Thus, the primary goal of this
study was to investigate the mechanism of IGF-I actions in
the proliferative effects of PDGF and FGF-2 on the O-2A
progenitor. We report here that IGF-I significantly enhances
the mitogenic actions of both PDGF and FGF-2 on O-2A
progenitors. We show that IGF-I synergizes with FGF-2 to
promote DNA synthesis in O-2A progenitors, while its
effect with PDGF on DNA synthesis is additive. Investiga-
tions into the mechanism of IGF-I action on O-2A progeni-
tors demonstrate that IGF-I has no significant effect on cell
cycle time. Instead, IGF-I promotes recruitment of addi-
tional O-2A progenitors into the S phase of the cell cycle.
MATERIALS AND METHODS
Materials
MEM cell culture media, fetal bovine serum, and trypsin were
purchased from Gibco-BRL (Long Island, NY). Recombinant human
or rat IGF-I was purchased from GroPep (Adelaide, Australia) or
Upstate Biochemicals (Lake Placid, NY). Recombinant human
FGF-2, PDGF, and NT-3 were purchased from R&D Systems
(Minneapolis, MN). [3H]Thymidine was purchased from DuPont-
NEN (Boston, MA). Cell culture media supplements and standard
laboratory reagents were purchased from Fisher Scientific (Pitts-
burgh, PA) or Sigma Chemical Company (St. Louis, MO).
O-2A Progenitor Cultures
Newborn rat forebrain cortices were enzymatically digested
with trypsin and DNase I and then mechanically dissociated and
plated in minimal essential medium containing 10% FBS with
antibiotics as previously described (Levison and McCarthy, 1991).
The cells were grown in T75 flasks, with media changed every 2–3
days until confluence was reached (10–14 days). At this time, the
culture consisted of a mixed glial population of astrocytes, oligo-
dendrocyte progenitors, and microglia. Microglia were separated by
shaking the flasks on a rotary shaker for 1.5 h at 260 rpm. The
flasks were then shaken for an additional 18 h at 260 rpm to
separate oligodendrocyte progenitors and astrocytes as described
(McCarthy and de Vellis, 1980). Isolated oligodendrocyte progeni-
tors (O-2As) were then seeded into poly-D-lysine-coated T75 flasks
in hormone-supplemented media at a density of 1.5 3 104/cm2. The
hormone-supplemented medium was a modified formula of the N2
chemically defined media called N2S. N2 medium was composed
of DMEM:F12 (GIBCO, Grand Island, NY; containing 15 mM
Hepes, 2 mM glutamine) supplemented with 0.66 mg/ml BSA, 10
ng/ml d-biotin, 5 mg/ml insulin, 20 nM progesterone, 100 mM
putrescine, 5 ng/ml selenium, 50 mg/ml apo-transferrin, 100 U/ml
s of reproduction in any form reserved.
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416 Jiang, Frederick, and Woodpenicillin, and 100 mg/ml streptomycin. B104-conditioned medium
CM) consisted of N2 medium that was preconditioned by B104
euroblastoma cells. The N2S medium was composed of 66% N2
edium, 34% B104 CM, 5 ng/ml FGF-2, and 0.5% fetal bovine
erum. O-2As rapidly proliferated in the N2S medium, and when
0% confluence was reached, papain was used for passage (Young
nd Levison, 1997). A greater than 95% purity of O-2A cells was
onsistently achieved with these enrichment and culture condi-
ions.
Analysis of DNA Synthesis by [3H]Thymidine
ncorporation
Seven to 12 days after amplification, the O-2A cells were plated
into 20 mg/ml poly-D-lysine-coated 24-well plates at a density of
4 3 104 cells/cm2 in N2S. Six wells were used for each treatment
condition. After 1 day, the cells were switched to hormone-
supplemented media with different growth factor treatments. The
hormone-supplemented medium was identical to the N2 medium
described above, with the exception that the insulin concentration
was lowered to 5 ng/ml, a concentration adequate to stimulate the
insulin receptor but not the IGF-IR (Rechler and Nissley, 1985).
Cells were treated for 24 h under one of the following conditions:
control medium, 10 ng/ml IGF-I alone, 10 ng/ml FGF-2 alone, 10
ng/ml PDGF-AA alone, 10 ng/ml NT-3 alone, or combinations of
these factors. [3H]Thymidine (final concentration of 4 mCi/ml) was
added to the cultures for the final 6 h of treatment. The O-2A cells
were fixed with cold 5% trichloroacetic acid (TCA) for 15 min,
washed with 5% TCA 3 3 5 min, and then lysed with 0.5 M NaOH
or 1 h at 37°C. Cell lysates from each well were then collected and
3H]thymidine incorporation was determined by liquid scintilla-
tion counting. Scintillation counts were expressed as disintegra-
tions per minute (dpm) and used in statistical analyses and to
determine the stimulation index. The stimulation index was
calculated according to the equation Stimulation index 5 mean
dpm treatment A/mean dpm treatment B, where treatment B
represents the control cultures unless otherwise stated. All growth
factor treatments were repeated in at least three independent
experiments.
Analysis of Cell Cycle Kinetics
Cells were plated into 24-well plates and 6 wells per plate were
treated with N2 control medium, IGF-I (10 ng/ml), FGF-2 (10
ng/ml), or a combination of IGF-I/FGF-2 (10 ng/ml each) as for
previous experiments. [3H]Thymidine was added 9.5 h after the
tart of growth factor treatment, and one plate of cells was
rocessed for thymidine incorporation every 1.5–2 h from 11 h
hrough 23 h. Data were analyzed by plotting the mean incorpora-
ion over time. Calculation of slope, peak incorporation, and time
o peak incorporation were obtained after converting and plotting
ata to natural log scale. Rates of incorporation were determined
rom the slopes analyzed between 11 and 14 h. Results from the
hymidine time course study were observed in two independent
xperiments.
Immunocytochemistry and BrdU Labeling
to Detect Cells in S Phase
Purified O-2A cells were prepared as described above and plated
onto poly-D-lysine-coated glass coverslips in 24-well plates. Cells
were maintained in HSM, with the addition of IGF-I (10 ng/ml),
Copyright © 2001 by Academic Press. All rightFGF-2 (10 ng/ml), or a combination of IGF-I/FGF-2 (10 ng/ml each)
and BrdU (50 mM final concentration; Sigma, St. Louis, MO) to
label cells undergoing DNA synthesis. In initial experiments, cells
were treated with growth factors for 18 h and BrdU was added to
the medium for the final 8 h. Subsequent experiments were
conducted for 15.5 h, with BrdU added to the medium for the final
30 min of treatment.
At the end of growth factor treatment, the cells growing on
coverslips were inverted face down onto slides with a silicon gasket
derived from Chamber Slides (Miles Laboratory) for immunocyto-
chemistry. Cells were fixed for 2 min in 2% paraformaldehyde and
rinsed twice in PBS. Supernatant from the A2B5 hybridoma was
diluted 1:3 in MEM supplemented with 10% bovine calf serum and
10% lamb serum with 15 mM Hepes. After 45 min of incubation at
room temperature in the A2B5 supernatant, cells were gently
washed 33 with MEM containing 10% bovine calf serum and 15
mM Hepes. Cells were then incubated for 45 min in goat anti-
mouse IgM-LRSC (1:200; Jackson Immunoresearch Laboratories,
West Grove, PA). The cells were washed 43 as described above,
refixed with 2% paraformaldehyde for 2 min, rinsed with PBS, and
treated with 2 N HCl for 15 min at room temperature to denature
the DNA in preparation for BrdU detection. Cells were then rinsed
with 0.1 M borate buffer (pH 8.5) to neutralize the HCl, rinsed in
PBS, and incubated in PGB Superblock (10% bovine serum albu-
min, 0.05% NaN3, 10% normal goat serum in PBS) for 1 h at room
temperature to block nonspecific binding. Cells were then incu-
bated with a mouse IgG1 antibody to BrdU (1:75; DAKO, Carpen-
teria, CA) in PGB diluent (PGB Superblock diluted 1:5 with PBS) for
1 h at room temperature. Cells were then rinsed in PBS and
incubated with FITC-conjugated goat anti-mouse IgG1 secondary
antibody (1:100; Southern Biotechnology Associates, Birmingham,
AL) in PGB diluent for 1 h at room temperature. DAPI (1 mg/ml)
as added to the secondary antibody solution to label cell nuclei.
overslips were then rinsed with PBS and mounted onto glass
lides. A minimum of three individual fields was analyzed on each
f three coverslips per treatment condition.
Statistical Analyses
Analysis of variance was used for group comparisons within an
experiment. For all thymidine incorporation experiments with
multiple comparisons, adjusted P values associated with posthoc
group comparisons were calculated using the Tukey method.
Differences in stimulation index between IGF-I-treated and control
groups were determined using an unpaired t test due to the small
magnitude of the response to IGF-I in comparison to the other
groups. For the time course data, piecewise linear regression was
used to estimate slope and peak parameters. Logarithmic transfor-
mation of thymidine counts measured as disintegrations per
minute (dpm) was employed to linearize the temporal response
pattern. All analyses were done using the SAS or Statview statis-
tical software programs.
RESULTS AND DISCUSSION
IGF-I Synergizes with FGF-2 to Induce DNA
Synthesis in O-2A Progenitors
Initial experiments were designed to test whether IGF-I
was a mitogen for O-2A progenitors either alone or in
combination with FGF-2 and PDGF. Enriched cultures of
s of reproduction in any form reserved.
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417IGF-I and FGF-2 Synergism on O-2A Progenitorscortical O-2A progenitors were treated for 24 h in serum-
free media containing IGF-I, FGF-2, or a combination of
IGF-I/FGF-2 in the presence of physiological levels of insu-
lin (5 ng/ml) (Fig. 1). Additional cultures were treated with
serum-free media containing micromolar levels of insulin
(5 mg/ml) with or without the addition of FGF-2 (Fig. 1). As
expected from previous studies, FGF-2 alone significantly
induced incorporation of thymidine into O-2A progenitors
compared to control cultures (3- to 6-fold; P , 0.01). In
contrast, treatment of cells with either micromolar levels of
insulin or nanomolar levels of IGF-I resulted in only a
minor induction of DNA synthesis that, in this experiment,
was not statistically significant. In other experiments, IGF-I
did significantly stimulate DNA synthesis but never more
than 2-fold over control cultures (discussed below). How-
ever, both IGF-I and micromolar levels of insulin signifi-
cantly increased the ability of FGF-2 to promote thymidine
incorporation into O-2A progenitors (by 10- to 13-fold
versus control cultures; P , 0.01). The ability of super-
physiological levels of insulin to mimic the effect of IGF-I
(Fig. 1) is consistent with the known ability of insulin at
micromolar concentrations to activate the IGF-IR (Rechler
and Nissley, 1985). The synergism between IGF-I and FGF-2
was observed in all experiments; however, the extent of
thymidine incorporation by FGF-2 alone and by the combi-
FIG. 1. Induction of DNA synthesis in O-2A progenitors treated
for 24 h with IGF-I or high insulin in the presence or the absence of
FGF-2. Enriched O-2A cells were treated for 24 h in HSM with the
addition of IGF-I, FGF-2, a combination of IGF-I 1 FGF-2, or no
growth factor treatment (control). HSM contained a physiological
level of insulin (5 ng/ml) and all growth factors were used at 10
ng/ml. Additional cultures were analyzed that contained 5 mg/ml of
insulin in the presence or the absence of FGF-2. [3H]Thymidine was
dded at 18 h and TCA-precipitable counts were determined at 24 h
ollowing the start of treatments. Values represent the mean 6SEM
or each condition (n 5 6). (a) P , 0.01 compared to control
conditions. (b) P , 0.01 compared to control conditions and FGF-2
conditions.nation of IGF-I/FGF-2 depended on the passage number of
Copyright © 2001 by Academic Press. All righthe O-2A progenitors prior to treatment (Table 1). Thus, in
ultures amplified for only 7 days in vitro (DIV), FGF-2
romoted a 20- to 21-fold increase in thymidine incorpora-
ion versus a 3- to 6-fold increase in the cultures amplified
or 12 DIV. These results suggest the possibility that FGF
eceptor numbers or other molecules in the FGF signaling
athway may be diminished over time in culture due either
o the inherent age of the progenitor cells themselves or to
heir response to the culture environment. Interestingly,
he extent of O-2A amplification did not significantly affect
GF-I-induced DNA synthesis that ranged from 1.1- to
.9-fold over control cultures in all experiments and was
tatistically significant in three of four experiments (P ,
.01; Table 1). Thus, regardless of the magnitude increase
n DNA synthesis in response to FGF-2, the combination of
GF-I/FGF-2 was always greater than additive.
Similar experiments were performed to test the effect of
GF-I on PDGF-stimulated DNA synthesis in O-2A progeni-
ors (Fig. 2). PDGF alone, in the absence of IGF-I or
icromolar levels of insulin, promoted incorporation of
hymidine into the cells by 2-fold over that of control
ultures (P # 0.01). IGF-I/PDGF increased thymidine
ncorporation by 2- to 2.5-fold over that of cultures treated
ith IGF-I alone (P , 0.01) and 1.5- to 2-fold over cultures
reated with PDGF alone (P , 0.01). Thus, in contrast to
he synergistic effect of IGF-I with FGF-2, the effect of IGF-I
ith PDGF was additive.
Since previous studies have demonstrated that IGF-I can
romote survival of O-2A progenitors, additional cells were
lated onto coverslips and used for monitoring cell viability
nder each growth factor condition. Assessment of both
ell number and nuclear morphology demonstrated no loss
f cells or compromise of cell viability during the 24-h
uration of our experiments in cultures lacking IGF-I com-
ared to those treated with IGF-I. Thus, survival effects of
TABLE 1
Time in Culture Decreases Response to FGF-2 and IGF-I/FGF-2
DIVa IGFIb FGF2b IGFI/FGF2b
IGFI/FGF2c
(vs FGF-2)
7 1.7d 21.4d 38.3d 1.8e
1.9d 19.8d 30.7d 1.6f
12 1.1 2.7d 10.3d 3.9f
1.4d 5.8d 13.3d 2.3f
a DIV, days in vitro.
b Values represent the stimulation index based on incorpora-
ion of [3H]thymidine where Stimulation index 5 mean dpm
xperimental/mean dpm control.
c Values represent the stimulation index based on incorpora-
tion of [3H]thymidine where Stimulation index 5 mean dpm
xperimental/mean dpm FGF-2.
d P , 0.01 compared to control.
e P , 0.05 compared to FGF-2.
f P , 0.01 compared to FGF-2.
s of reproduction in any form reserved.
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418 Jiang, Frederick, and WoodIGF-I did not contribute to our results showing IGF-I
enhancement of FGF-2- and PDGF-mediated proliferation
of O-2A progenitors.
Comparison of Growth Factor Combinations
for Maximal Stimulation of DNA Synthesis
in O-2A Progenitors
Since FGF-2 and PDGF are widely used in combination to
amplify O-2A progenitors in vitro, we compared stimula-
ion of thymidine incorporation in O-2As by FGF-2/PDGF
ith the combination of IGF-I/FGF-2 and with the triple
ombination of IGF-I/FGF-2/PDGF. As shown in Fig. 3, all
rowth factor treatments significantly increased DNA syn-
hesis over control cultures (P , 0.01). The combination
treatments, FGF-2/PDGF, IGF-I/FGF-2, and IGF-I/FGF-2/
PDGF, further enhanced thymidine incorporation over
FGF-2 alone by 1.8-, 2.3-, and 2.6-fold, respectively (P ,
0.01). In addition, IGF-I/FGF-2 and IGF-I/FGF-2/PDGF sig-
nificantly increased thymidine incorporation by 1.3- to
1.5-fold over the FGF-2/PDGF combination (P 5 0.01). No
ignificant differences were seen between the IGF-I/FGF-2
ombination and the triple IGF-I/FGF-2/PDGF combina-
ion. These results were consistent across experiments with
oth low (7 DIV) and high (12 DIV) passage cells, with the
xception of the PDGF/FGF-2 combination. The addition of
DGF to FGF-2 was significant only in the higher passage
ells, where the effect of FGF-2 by itself was less robust
FIG. 2. Induction of DNA synthesis in O-2A progenitors treated
for 24 h with IGF-I, PDGF, or IGF-I/PDGF. Enriched O-2A cells
were treated for 24 h in HSM with the addition of IGF-I, PDGF,
IGF-I 1 PDGF in combination, or no growth factor treatment
control). HSM contained a physiological level of insulin (5 ng/ml)
nd all growth factors were used at 10 ng/ml. [3H]Thymidine was
added 18 h following growth factor treatment and TCA-
precipitable counts were determined at 24 h following the start of
treatments. Values represent the mean 6SEM for each condition
(n 5 6). (a) P # 0.05 compared to control. (b) P , 0.01 compared
o control. (c) P , 0.01 compared to PDGF and IGF-I alone.data not shown). c
Copyright © 2001 by Academic Press. All rightThe results of these experiments support a model of
aximal combined growth factor stimulation that includes
GF-I (or micromolar levels of insulin) with FGF-2 and
DGF. Moreover, IGF-I in combination with FGF-2 was
ignificantly better at promoting DNA synthesis than was
GF-2/PDGF, the most commonly reported growth factor
ombination used to promote proliferation of O-2A progeni-
ors. In these studies, we found that the combination of
GF-I/FGF-2 was equivalent to the triple combination of
GF-I/FGF-2/PDGF in promoting DNA synthesis in the
-2A progenitors. Taken together, these results suggest
hat FGF-2 is a critical mitogen for the O-2A progenitors
nd that the combination of FGF-2 with IGF-I promotes
aximal stimulation of DNA synthesis in O-2A progeni-
ors.
Effect of IGF-I/FGF-2 on Cell Cycle Kinetics
of O-2A Progenitors
The distinct and dramatic effect of IGF-I on FGF-2-
stimulated DNA synthesis in the O-2A progenitors sup-
ports the hypothesis that IGF-I in the presence of FGF-2,
can promote cell cycle progression in these progenitors.
Two possible mechanisms by which IGF-I could enhance
DNA synthesis in the O-2A cultures treated with FGF-2 are
(1) by shortening the cell cycle time or (2) by recruiting
FIG. 3. Induction of DNA synthesis in O-2A progenitors follow-
ing treatment with various growth factor combinations for 24 h.
Enriched O-2A cells were treated in HSM with the addition of
FGF-2, FGF-2 1 PDGF in combination, FGF-2 1 IGF-I in combi-
ation, FGF-2 1 IGF-I 1 PDGF in combination, or no growth factor
reatment (control). HSM contained a physiological level of insulin
5 ng/ml) and all growth factors were used at 10 ng/ml. [3H]Thy-
midine was added 18 h following growth factor treatment and
TCA-precipitable counts were determined at 24 h following the
start of treatments. Values represent the mean 6SEM for each
condition (n 5 6). (a) P , 0.01 compared to control. (b) P , 0.01
ompared to FGF-2 alone. (c) P , 0.01 compared to FGF-2/PDGF.
s of reproduction in any form reserved.
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419IGF-I and FGF-2 Synergism on O-2A Progenitorsadditional cells into the cell cycle. In order to test these
alternatives, we designed experiments to analyze the kinet-
ics of thymidine incorporation as well as the proportion of
cells in S phase at the time of peak thymidine incorporation
following growth factor treatment. To analyze the kinetics
of the cell cycle in cultures of O-2A progenitors treated
with IGF-I, FGF-2, or a combination of IGF-I/FGF-2, the
time course of thymidine incorporation was determined
using a cumulative labeling paradigm (Fig. 4). Consistent
with our previous observations, FGF-2-treated O-2As had a
significantly greater peak of thymidine incorporation than
either control cultures or IGF-I-treated cultures (P ,
0.001). Also as expected, the peak of thymidine incorpora-
tion was significantly greater in cells treated with the
combination of IGF-I/FGF-2 than in those treated with
FGF-2 alone (P , 0.001). The rate of thymidine synthesis
as determined from the slope of the lines between 11 and
14 h, however, revealed no significant differences between
treatment groups, with the exception of IGF-I (slope 5
0.3982) versus IGF-I/FGF-2 (slope 5 0.4851; P , 0.001). Of
articular importance is that the rate of thymidine incor-
oration for IGF-I/FGF-2 (slope 5 0.4851) did not differ
ignificantly from that of FGF-2 alone (slope 5 0.4434).
-2As treated with IGF-I alone exhibited an incorporation
rofile similar to that of untreated cells. The slower rate of
hymidine incorporation in the IGF-I-treated cells was also
eflected in the time at which maximal thymidine incorpo-
ation was obtained. Control cultures reached maximal
hymidine incorporation at 14 h, while FGF-2- and IGF-I/
GF-2-treated cultures reached maximal incorporation at
5.5 h. In contrast, IGF-I-treated cells continued to increase
hymidine labeling until 17 h following start of growth
actor treatment. The results of the kinetic analyses show-
ng similar rates of thymidine incorporation between
FIG. 4. Time course study showing incorporation of [3H]Thymi
treatment. Data are represented as mean TCA-precipitable counts 6
of dpm 6SEM (B). Slopes were calculated between 11 and 14 h from
GF-I; () FGF-2; (}) IGF-I/FGF-2.GF-2- and IGF-I/FGF-2-treated cultures supports the con-
Copyright © 2001 by Academic Press. All rightlusion that differences in cell cycle time did not contribute
ignificantly to the differences observed in peak thymidine
ncorporation at 24 h between these two treatment groups.
hus, these results suggest a mechanism of IGF action that
s distinct from effects on the rate of cell cycle progression
n O-2A progenitors treated with FGF-2.
IGF-I in the Presence of FGF-2 Increases the
Proportion of O-2A Progenitors in S Phase
To determine whether IGF-I/FGF-2 increased DNA syn-
thesis in O-2A progenitors by regulating the proportion of
cells entering S phase, we analyzed cells in individual
cultures following treatment with growth factors in the
presence of BrdU. The proportion of O-2A progenitors in S
phase was determined by counting cells double immunopo-
sitive for BrdU and the A2B5 antigen, a marker for the O-2A
progenitor. In initial experiments where cells were labeled
with BrdU for 8 h, we confirmed that incorporation of BrdU
by A2B5-positive cells was significantly increased in FGF-2-
and IGF-I/FGF-2-treated cultures compared to control cul-
tures in proportion to results obtained for the thymidine
incorporation studies (Fig. 5). However, since accumulation
of BrdU over 8 h could reflect differences in both the rate of
cell cycle progression and the number of cycling cells,
experiments were designed to determine the exact propor-
tion of A2B5-positive cells in S phase at 15–15.5 h following
the addition of growth factors. The time of 15 h was chosen
to correspond with the time of maximal difference in
thymidine incorporation observed in the kinetic analysis.
Cultures of O-2A progenitors were treated with IGF-I,
FGF-2, IGF-I/FGF-2, or without growth factors as for previ-
ous experiments. Fifteen hours after the start of growth
factor treatment, cells were pulsed with BrdU for 30 min, a
into O-2As between 11 and 23 h after the start of growth factor
at each time point (A) or plotted as a logarithmic transformation
a analyzed by piecewise linear regression (n 5 6). (n ) Control; (F)dine
SEM
datperiod of time in which cells already in S phase were labeled
s of reproduction in any form reserved.
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420 Jiang, Frederick, and Woodbut that precluded significant labeling by cells traversing
G1 and entering S phase. The number of O-2A progenitors
undergoing DNA synthesis was determined by counting
cells immunopositive for both BrdU and the A2B5 antigen
(Fig. 6). As expected, FGF-2 significantly increased the
percentage of O-2A progenitors in S phase compared to
control cultures (P , 0.02). However, IGF-I in combination
ith FGF-2 nearly doubled the percentage of O-2A cells in
phase compared to cultures treated with FGF-2 alone (P ,
.002). These results demonstrate that IGF-I synergizes
ith FGF-2 by recruiting additional progenitors into the
ell cycle.
The studies presented here demonstrate that IGF-I sig-
ificantly enhances the ability of FGF-2 and PDGF to
romote DNA synthesis in O-2A progenitors. Of greatest
ignificance is our finding that IGF-I synergizes with FGF-2
n promoting the incorporation of thymidine into these
ells and that the mechanism for this synergism includes
ncreased recruitment of progenitor cells into the cell cycle.
hese results are consistent with a competence/progression
actor model for the O-2A progenitors. The concept of
ompetence and progression factors in promoting progres-
ion of cells past G1 checkpoints and into the S phase of the
ell cycle was first proposed for fibroblasts (Pledger et al.,
977; Scher et al., 1979; Stiles et al., 1979). In fibroblasts,
DGF acts as a competence factor to promote fibroblast cell
ntry into G1 but the presence of a progression factor (such
s platelet-poor plasma or IGF-I) is also required for the cells
o pass the G1 restriction point and enter S phase. Based on
ata presented here, we propose a similar model for the
roliferation of O-2A progenitors where FGF-2 and PDGF
re competence factors and IGF-I is a progression factor for
he O-2A progenitors.
The profiles of incorporation observed in the kinetic
xperiments suggest that the O-2A cells are largely syn-
hronized with reference to the cell cycle in our cultures.
his is consistent with the idea that progression through
1 is the longest phase of the cell cycle and the major point
f regulation. Thus, following harvesting and replating, the
ddition of mitogens to the cells initiates their progression
hrough G1 and into S. Further evidence that the O-2A cells
n our cultures are largely synchronized comes from pre-
iminary data indicating that G1 cyclins are induced by
6–18 h, while the levels of G2 cyclins do not increase until
4 h following growth factor addition in similarly treated
ultures (T. J. Frederick and T. L. Wood, unpublished data).
Taken together with previous data, our results support
he hypothesis that IGF-I has a major role in enhancing the
ctions of other factors on O-2A progenitors. The data
resented here indicate that, by itself, IGF-I is not a strong
itogen for O-2A progenitors but does have a significant
ffect on proliferation of the O-2A progenitors when in the
resence of FGF-2 and PDGF. An essential role for IGF-I in
romoting actions of other growth factors is not limited to
ells of the O-2A lineage. Specifically, IGF-I has been shown
o promote the mitogenic actions of FGF-2 in several othert
cell types, including mouse neuroepeithelial cells (Drago et
Copyright © 2001 by Academic Press. All rights of reproduction in any form reserved.
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421IGF-I and FGF-2 Synergism on O-2A Progenitorsal., 1991) and rabbit vascular smooth muscle cells (Reape et
l., 1996). Interestingly, in another study on rat cortical
rogenitors it was reported that FGF-2 increased recruit-
ent of these progenitor cells into the cell cycle (Cavanagh
t al., 1997). It is of particular interest that these studies
ere conducted on cortical progenitors cultured in media
ontaining micromolar levels of insulin; however, it was
ot determined whether stimulation of the IGF receptor
as critical for the mitogenic effects of FGF-2 on the
ortical progenitors in these experiments. IGF-I has also
een reported to enhance PDGF-stimulated mitogenesis in
ascular smooth muscle cells (Thommes et al., 1996). The
mechanisms for the interaction of IGF-I with FGF-2 and
PDGF in these studies are unclear; however, one mecha-
nism may be through induction of IGF-IR mRNA and
promoter activity, as demonstrated for both FGF-2 and
PDGF-BB in various cell types in vitro (Hernandez-Sanchez
et al., 1997; Rubini et al., 1994). In addition to enhancing
proliferation of O-2A progenitors, previous studies have
shown that IGF-I also promotes the survival of both oligo-
dendrocyte progenitors and of mature oligodendrocytes
(Barres et al., 1992, 1993; Ye and D’Ercole, 1999). Similar to
its ability to function coordinately with other mitogens,
IGF-I cooperates with two other families of survival factors,
the neurotrophins and the CNTF/LIF family of cytokines,
to promote maximal survival of O-2A lineage cells (Barres
et al., 1993).
FIG. 6. Proportion of A2B51/BrdU1 cells following 15.5 h of
growth factor treatment and following a 30-min pulse of BrdU.
Enriched O-2A cells were treated with IGF-I, FGF-2, or IGF-I/FGF-2
or without growth factors (control) for 15 h. BrdU was added to the
media for an additional 30 min. The percentages of BrdU1/A2B51
cells were determined from counting randomly chosen fields on
three coverslips per treatment condition. Differences between
groups were determined by ANOVA followed by Fisher’s protected
least significant difference posthoc test. (a) P , 0.02 compared to
ontrol or to IGF-I alone. (b) P , 0.01 compared to FGF-2 alone.In addition to the presence or the absence of other growth
Copyright © 2001 by Academic Press. All rightfactors, the effect of IGF-I on cells of the O-2A lineage also
depends on the maturation stage of these cells. While the
predominant effect of IGF-I on the O-2A progenitor is in
proliferation and survival, numerous studies have shown
that IGF-I promotes maturation and myelin production in
immature and mature oligodendrocytes both in vitro and in
vivo (Carson et al., 1993; McMorris et al., 1993; Ye et al.,
1995a,b). The ability of IGF-I to promote oligodendrocyte
survival and myelin production has been the basis of its
proposed use in demyelinating diseases (McMorris and
McKinnon, 1996; Webster, 1997). Indeed, IGF-I reduced
clinical deficits and lesion severity in acute and chronic
relapsing EAE models in rats (Li et al., 1998; Liu et al., 1995;
Yao et al., 1996) and decreased oligodendrocyte apoptosis
after cuprizone-induced demyelination in mice (Mason et
al., 2000). In vitro, IGF-I also promoted myelination in
cultured mouse embryonic nerve tissue following
complement-mediated demyelination (Roth et al., 1995).
The ability of IGF-I to amplify the effects of FGF-2 and
PDGF on the proliferation of oligodendrocyte progenitors
raises the additional possibility that it also could be useful
in combination with these mitogens to promote the gen-
eration of additional oligodendrocytes during the acute
demyelinating stage. This is of particular importance if the
presence of IGF-I increases the recruitment of quiescent
progenitors into the cell cycle, as shown here for the
combination of IGF-I and FGF-2. Finally, these studies
provide evidence that the effects of a growth factor on a
progenitor cell are profoundly influenced by the intrinsic
program and developmental stage of that cell as well as by
the presence or the absence of other factors in the environ-
ment in which the progenitor cell exists.
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